Lupin

By Research Desk
about 11 years ago
Lupin

 

The stock was yesterday amongst the top gainers on the BSE when it closed, buoyed by the very good Q3FY14 numbers. The company posted a 42% (YoY) rise in consolidated net profit at Rs.476 crore on a 21% jump in net sales at Rs.2983 crore. EBITDA was up 28% at Rs.773 crore while margins were very healthy, up 140 bps at 25.6%. Forex gain of Rs.25 crore also helped shore the bottomline.

This performance was driven by a robust 31% growth in formulations in USA, contributing 45% to total sales, while revenue from India contributed 22% to the total sales rose 14%. Sales from Japan were muted, showing a growth of 2%. The company launched 5 new products in USA during the quarter and with this, its total tally is 62 products. Revenue expenditure on R&D stood at 9.1% of net sales. The company is debt free at the net debt level and this was reflected in the interest outgo, which YoY was down 46%. Lupin filed 5 ANDAs and received 5 ANDA approvals in the quarter and cumulative ANDA filings with the US FDA now stand at 186 with the company having received 96 approvals to date. It also received 5 approvals from European regulatory authorities in the quarter. The company, for 9MFY14, posted a consolidated net profit at Rs.1283 crore and with one more quarter to go, it is sure to surpass that of FY13 at Rs.1314 crore.

2016.4 (-22.30)

Popular Comments

No comment posted for this article.